Share This Page
Drug Price Trends for LEVONOR-ETH ESTRAD TRIPHASIC
✉ Email this page to a colleague
Average Pharmacy Cost for LEVONOR-ETH ESTRAD TRIPHASIC
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LEVONOR-ETH ESTRAD TRIPHASIC | 68180-0857-73 | 0.35815 | EACH | 2025-03-19 |
| LEVONOR-ETH ESTRAD TRIPHASIC | 68180-0857-71 | 0.35815 | EACH | 2025-03-19 |
| LEVONOR-ETH ESTRAD TRIPHASIC | 68180-0857-73 | 0.34029 | EACH | 2025-02-19 |
| LEVONOR-ETH ESTRAD TRIPHASIC | 68180-0857-71 | 0.34029 | EACH | 2025-02-19 |
| LEVONOR-ETH ESTRAD TRIPHASIC | 68180-0857-73 | 0.29784 | EACH | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Levonorgestrel and Ethinyl Estradiol Triphasic
Introduction
Levonorgestrel and ethinyl estradiol, commonly known as LEVONOR-ETH ESTRAD, are key components of oral contraceptive pills (OCPs) that are widely used for birth control and other gynecological indications. This article delves into the market analysis and price projections for the triphasic formulation of this drug.
Market Size and Growth
The global market for levonorgestrel API, a crucial component of these OCPs, is expected to grow steadily. As of 2023, the market size was valued at USD 0.05 billion and is projected to reach USD 0.07 billion by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 4%[3].
Driving Factors
Several factors drive the growth of the levonorgestrel API market, including:
- Non-Contraceptive Benefits: Levonorgestrel has various non-contraceptive benefits, such as treating menorrhagia, which contributes to its market growth[3].
- Contraceptive Demand: The demand for effective and reliable contraceptives continues to drive the market for levonorgestrel and ethinyl estradiol formulations.
- Pharmaceutical Innovations: Advances in pharmaceutical technology and the development of new formulations, such as triphasic and extended-cycle options, also contribute to market expansion.
Key Players
The levonorgestrel API market is dominated by several key players, including:
- Bayer HealthCare
- Qinhuangdao Zizhu Pharmaceutical
- Yangzhou Pharmaceutical
- Lupin
- Hubei Gedian Humanwell
- Sterling Spa[3]
These companies play a significant role in manufacturing and distributing levonorgestrel and ethinyl estradiol products globally.
Pricing Analysis
The pricing of levonorgestrel and ethinyl estradiol triphasic tablets can vary based on several factors, including the pharmacy, location, and availability of generic versions.
Current Pricing
- The cost for a triphasic oral tablet of levonorgestrel and ethinyl estradiol can range from $35.36 for a supply of 84 tablets to around $61 for a supply of 168 tablets, depending on the pharmacy and the use of discount cards[2][5].
Price Projections
Given the stable demand and moderate growth rate of the levonorgestrel API market, it is likely that prices will remain relatively stable or see minor increases. Here are some key points to consider:
- Generic Versions: The availability of generic versions tends to keep prices competitive. For instance, generic versions of levonorgestrel and ethinyl estradiol triphasic tablets are available from $35.36 for 84 tablets[2][5].
- Pharmacy Variations: Prices can vary significantly depending on the pharmacy, with some offering lower prices due to discount cards or promotions.
- Market Competition: The presence of multiple manufacturers and the competition among them help in maintaining competitive pricing.
Clinical and Patient Preferences
Efficacy and Side Effects
Clinical studies have shown that both monophasic and triphasic formulations of levonorgestrel and ethinyl estradiol have similar patient satisfaction and side effect profiles, except for breakthrough bleeding and spotting, which are less common in the triphasic formulation[1].
Patient Acceptance
Patient acceptance is a crucial factor in the market success of any contraceptive. The triphasic formulation, with its phased hormone delivery, is often preferred by some patients due to its lower incidence of breakthrough bleeding and spotting.
Contraindications and Safety Considerations
While levonorgestrel and ethinyl estradiol are generally safe and effective, there are certain contraindications and safety considerations:
- Thromboembolic Disorders: These medications are contraindicated in women with a history of thrombophlebitis or thromboembolic disorders[4].
- Hepatic and Cerebral-Vascular Conditions: They are also contraindicated in women with certain hepatic and cerebral-vascular conditions[4].
Market Trends
Extended-Cycle Options
There is a growing trend towards extended-cycle oral contraceptives, which reduce the frequency of menstrual periods. These options are becoming increasingly popular due to their convenience and reduced menstrual-related symptoms[2].
Generic and Brand Name Options
The availability of both generic and brand name versions of levonorgestrel and ethinyl estradiol triphasic tablets provides consumers with a range of choices, influencing market dynamics and pricing.
Key Takeaways
- Market Growth: The levonorgestrel API market is expected to grow at a CAGR of 4% until 2032.
- Pricing Stability: Prices for levonorgestrel and ethinyl estradiol triphasic tablets are likely to remain stable due to competition and the availability of generic versions.
- Clinical Preferences: The triphasic formulation is preferred by some patients due to its lower incidence of breakthrough bleeding and spotting.
- Safety Considerations: It is crucial to consider contraindications and safety guidelines when prescribing these medications.
FAQs
1. What is the projected market size of the levonorgestrel API market by 2032? The global levonorgestrel API market is projected to reach USD 0.07 billion by 2032[3].
2. What are the driving factors for the growth of the levonorgestrel API market? The growth is driven by non-contraceptive benefits of levonorgestrel, its suitability to treat menorrhagia, and the ongoing demand for effective contraceptives[3].
3. Which companies are key players in the levonorgestrel API market? Key players include Bayer HealthCare, Qinhuangdao Zizhu Pharmaceutical, Yangzhou Pharmaceutical, Lupin, Hubei Gedian Humanwell, and Sterling Spa[3].
4. How do the prices of levonorgestrel and ethinyl estradiol triphasic tablets vary? Prices can range from $35.36 for 84 tablets to around $61 for 168 tablets, depending on the pharmacy and the use of discount cards[2][5].
5. What are the clinical advantages of the triphasic formulation over the monophasic formulation? The triphasic formulation has a lower incidence of breakthrough bleeding and spotting compared to the monophasic formulation[1].
Sources
- A comparison between monophasic levonorgestrel-ethinyl estradiol ... - PubMed
- Ethinyl estradiol/levonorgestrel Prices, Coupons, Copay Cards ... - Drugs.com
- Levonorgestrel API Market Size, Share - [2024 To 2032] - Business Research Insights
- Levonorgestrel and Ethinyl Estradiol: Package Insert / Prescribing Info - Drugs.com
- Levonest Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
More… ↓
